Aarti Drugs Limited has announced its financial results for the second quarter of FY25, reporting a decrease in both revenue and profit compared to the same period in the previous year.
Key Financial Highlights (Q2 FY25 vs Q2 FY24):
- Revenue from operations: ₹543.09 crore, down 6.3% from ₹577.54 crore in Q2 FY24.
- Total income: ₹543.47 crore, a decrease of 6.2% compared to ₹578.28 crore in Q2 FY24.
- Profit before tax (PBT): ₹40.99 crore, marking a 12.5% decline from ₹46.83 crore in the same quarter last year.
- Profit after tax (PAT): ₹30.39 crore, down 12.1% from ₹34.58 crore in Q2 FY24.
- Total expenses: ₹502.58 crore, slightly lower by 5.4% compared to ₹531.45 crore in the previous year’s quarter.
The results reflect a challenging quarter for Aarti Drugs as both revenue and profitability fell year-on-year. The company will need to focus on managing expenses and enhancing operational efficiencies to address these challenges moving forward.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. The author or Business Upturn is not liable for any losses arising from the use of this information.
